Our findings elucidate the interactions between ubiquitination and phosphorylation in the regulation of FOXP1 stability, positioning the FBXO44/FOXP1 pathway as a viable target for therapeutic strategies in CRC. This evidence concerns the gene FBXO44 and colorectal carcinoma.